All In Biotech

Drug Trial Radar · NCT00314704

Dopamine and Norepinephrine in Shock Patients

Comparison of Dopamine and Norepinephrine as the First Vasopressor Agent in the Management of Shock

Last checked: Nov 20, 2026Latest source record: Feb 1, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,679 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,679

Actual

Start

Dec 2003

Primary completion

Oct 2007

Study completion Oct 2007

Sponsor

Lead sponsor
Sepsis Occurrence in Acutely Ill PatientsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 14, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy of dopamine and norepinephrine, two commonly used vasopressor agents, in the treatment of shock.

Conditions

  • Shock

Interventions

  • dopamine versus norepinephrineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 28 day survival

Locations

8 sites in 3 countries. Site status is shown where the registry gives one.

  • University Hospital of Vienna

    Vienna, Austria

  • CHU Saint Pierre

    Brussels, Belgium

  • CHU Brugmann

    Brussels, Belgium

  • HIS Ixelles

    Brussels, Belgium

  • Erasme University Hospital

    Brussels, Belgium

  • St Elisabeth

    Brussels, Belgium

  • CHU Charleroi

    Charleroi, Belgium

  • Hospital Universitario Rio Hortega

    Valladolid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.